The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.

Biosimilars Forum 2019 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.

Join us in Mexico and trigger a quantum leap in Latin American Healthcare!

Who will
you meet?


More than:









Service Providers

Government Agencies

Industry Executives from Latam

From these areas:
  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing


Regulatory Framework in Brazil and Mexico

Maria Fernanda Thees ANVISA, Brazil Health Regulation and Surveillance Specialist


Current Development and Regulatory Challenges in the Region

Éctor Jaime Ramírez

National Action Party of Guanajuato, Mexico

Federal Deputy LXIV Legislature and Secretary of the Health Commission

Ricardo Castro

Neolpharma, Mexico

Biotechnology Manager

New Commercial Agreements in the region How to Make a Commercial Decision Based on Competitors and Management Models to Boost Biosimilars

Eduardo Cioppi

mAbxience, Argentina

Regional Director – Latin America

Nicolas Linares, sent

Ultragenyx Pharmaceutical, Mexico

Executive Director & General Manager

Expectations from the Mexican Academy

Laura Palomares,

UNAM, Mexico

Researcher and Professor

Regulatory Harmonisation Activities by Brazil and Mexico

Maria Fernanda Thees
ANVISA, Brazil
Health Regulation and Surveillance Specialist


Pharmacovigilance. Signal Management. Safety Surveillance. Risk communication

Nestor Lago

Gemabiotech, Argentina

Medical Director



The production of biologic-based pharmaceuticals is long and complex. Rapid answers from in-process controls confirm your production process is operating as designed—efficiently confirming product quality. With the most comprehensive portfolio of microbiology solutions for bioproduction, bioMérieux helps protect your customers, keep you in compliance, and improve your bottom line.

Becton Dickinson and Company

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories.



General Electric Healthcare


UDIBI se localiza en la Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, en la Ciudad de México. En UDIBI contamos con un equipo multidisciplinario de profesionales altamente calificados en el descubrimiento, desarrollo, producción y caracterización de productos farmacéuticos capaces de brindar soluciones que satisfagan a nuestros clientes.



Photo Gallery from Previous Events


Keep me updated